Compare FNWD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | IFRX |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.1M | 225.5M |
| IPO Year | 1996 | 2017 |
| Metric | FNWD | IFRX |
|---|---|---|
| Price | $41.38 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.29 |
| AVG Volume (30 Days) | 9.9K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | $31.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.05 | $0.80 |
| 52 Week High | $45.90 | $2.95 |
| Indicator | FNWD | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 27.04 |
| Support Level | $40.66 | $0.81 |
| Resistance Level | $44.01 | $1.07 |
| Average True Range (ATR) | 0.69 | 0.15 |
| MACD | -0.31 | -0.02 |
| Stochastic Oscillator | 3.53 | 0.00 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.